Exelixis(US:EXEL)2025-05-13 22:33Financial Performance - U S cabozantinib franchise net product revenues grew 36% year-over-year to $513 3 million in Q1 2025, compared to $378 5 million in Q1 2024[15, 27] - Total revenues for Q1 2025 were $555 4 million, a 31% increase compared to $425 2 million in Q1 2024[27, 40] - GAAP net income for Q1 2025 was $159 6 million, a significant increase from $37 3 million in Q1 2024[36, 40] - GAAP diluted earnings per share (EPS) increased to $0 55 in Q1 2025, compared to $0 12 in Q1 2024[39, 40] - The company increased its full-year 2025 financial guidance for net product revenues to $2 05 billion - $2 15 billion and total revenues to $2 25 billion - $2 35 billion[15, 43] - Approximately $1 5 billion of stock has been repurchased since March 2023, at an average price of $24 62 per share[42] CABOMETYX Performance - CABOMETYX holds approximately 44% TRx market share in Q1 2025[55] - CABOMETYX new patient starts reached an all-time high in Q1 2025[56, 62] - CABOMETYX in combination with nivolumab is the 1 prescribed TKI+IO regimen in 1L RCC[50, 56, 62] Pipeline and Development - The company anticipates pivotal data milestones for zanzalintinib in the second half of 2025, including top-line results for STELLAR-303 in CRC and STELLAR-304 in nccRCC[22]